Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

LIVN - LivaNova PLC Последние новости | Finranks

Home

LIVN

(LIVN)

NMS – Цена в реальном времени. Валюта: USD

61.85

-1.80 (-2.83%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

61.85

0.00 (0.00%)

После закрытия: Mar 27, 2026, 5:20 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

LivaNova Expands OSA Care With FDA-Approved aura6000 System

LivaNova Expands OSA Care With FDA-Approved aura6000 System

LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.

LivaNova to Announce First-Quarter 2026 Results

LivaNova to Announce First-Quarter 2026 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen.

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index (AHI) between 15 and 65.

Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)

Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)

The heavy selling pressure might have exhausted for LivaNova (LIVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy

All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy

LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Artisan International Small-Mid Fund Q4 2025 Performance Review

Artisan International Small-Mid Fund Q4 2025 Performance Review

The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display